American Made Advocacy: How Congress Can Restore the U.S. Printed Circuit Board Industry
Defense Speak Interpreted: Weapons—Electrical Power vs. Energetics
The Government Circuit: USMCA Review—A Crucial Opportunity to Fortify North American Electronics
U.S. DOD Awards $5.1M to Humanetics for Continued Development of Radiation Countermeasure
June 22, 2022 | Business WireEstimated reading time: 1 minute
Minneapolis-based Humanetics Corporation (Humanetics) has entered into a new $5.1 million cooperative research agreement with the U.S. Department of Defense (DOD) to continue advanced development of BIO 300, a medical countermeasure to protect military personnel and first responders from the harm caused by radiation exposure.
The new funding will be used to create, manufacture, and test a new formulation of BIO 300 that can be self-administered using an auto injector. Auto injectors are commonly used by the military to deliver fast-acting drugs such as atropine and naloxone. This new formulation of BIO 300 will complement the existing suite of oral formulations in the Humanetics portfolio that have been tested extensively and are in phase 2 trials. It is envisioned that the DOD would have access to both oral and auto injectable forms of BIO 300, which each have a unique use case.
“With the increasing potential for use of radiological or nuclear weaponry in the current global environment, especially with events in Ukraine, it’s a strategic imperative to protect our armed forces and first responders from radiation exposure and enable them to operate in areas of concern,” said Ronald Zenk, President and CEO at Humanetics.
BIO 300’s radioprotective attributes were originally discovered by researchers within the DOD at the Armed Forces Radiobiology Research Institute. The drug was licensed to Humanetics Corporation, which is leading its advanced development toward FDA approval. In parallel to the drug’s development for use as a medical countermeasure, Humanetics is evaluating the drug in clinical trials to determine its potential to reduce the toxic side effects of radiation in cancer patients and to reduce lung damage in COVID-19 long-haulers.
“We are enthused and encouraged by the DOD’s continued investment in the development of BIO 300 as a medical countermeasure,” said Zenk. “We see this drug not only providing protection for our warfighters, but also for our embassy personnel around the world and civilian populations who are at risk of radiation exposure from nuclear incidents and, furthermore, to improve the lives of cancer and COVID-19 patients.”
Share on:
Testimonial
"We’re proud to call I-Connect007 a trusted partner. Their innovative approach and industry insight made our podcast collaboration a success by connecting us with the right audience and delivering real results."
Julia McCaffrey - NCAB GroupSuggested Items
Mil Aero High Speed Connectors Market Report 2026: $7.41 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F
01/20/2026 | GlobeNewswireThe Mil Aero High-Speed Connectors Market Global Report 2026 offers strategists, marketers, and senior management the essential data to evaluate this swiftly developing market. The report predicts and analyzes trends that will influence the sector in the next decade and beyond, providing a roadmap to capture emerging opportunities.
Teledyne FLIR Wins $32M Recon Surveillance Contract in Bulgaria
01/15/2026 | BUSINESS WIRETeledyne FLIR Defense, part of Teledyne Technologies Incorporated, announced that it has been awarded a contract by the U.S. Army worth up to $32 million to deliver and integrate advanced electro-optical (EO/IR) systems for the Stryker Infantry Carrier Vehicle (ICV) Recon Kit.
Inside the Fight for U.S. Advanced Packaging: Military Electronics Experts Weigh In
12/15/2025 | I-Connect007 Editorial TeamModern warfare—driven by rapid evolution of UAVs, autonomous systems, and high-speed sensing—has made it clear that U.S. defense electronics must move beyond legacy architectures and embrace UHDI, advanced substrates, and next-generation interconnect technologies. In this roundtable discussion, two defense electronics experts outline a central challenge: The U.S. cannot field high-performance systems or maintain technological advantage while relying on overseas PCB, substrate, and component supply chains.
Your 2026 Business Playbook: Step 1: Strategy Isn’t a Document, It’s a Commitment
12/10/2025 | Dan Beaulieu, D.B. Management GroupLet’s start with a tough truth most companies don’t want to hear: Strategy is not a binder, a spreadsheet, or a deck of slides. It is a commitment to what you will do every day. Yet every December and January, companies all over this industry gather the troops at a conference table, eat a few muffins, and create what can only be described as an annual work of fiction, otherwise known as the “strategic plan.”
U.S. Defends Space Interests in Partnership with Allies: CSpO Initiative to Advance Coalition Spacepower
12/08/2025 | U.S. Department of WarU.S. military officials joined leaders from all 10 nations of the Combined Space Operations (CSpO) Initiative at the new French Space Command Headquarters this week, where they reaffirmed the strength and relevance of CSpO to deterrence, interoperability, and space warfighting capability.